Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyVisceral SurgeryDiseaseColon CancerEsophageal CancerFallopian Tube CarcinomaGastric CancerOvarian TumorPeritoneal Carcinomatosis, SecondarySubgroupAdenocarcinoma of the esophagogastric junction (AEG)ICD10C15.-C16.-C16.0C18.0C18.2C18.3C18.4C18.5C18.6C18.7C18.8C19C56C57.0C78.6MeSHCarcinoma, Ovarian EpithelialColorectal NeoplasmsEsophageal NeoplasmsFallopian Tube NeoplasmsOvarian NeoplasmsPeritoneal NeoplasmsStomach NeoplasmsSequenceChemotherapyChemo-substanceCisplatinFluorouracilMitomycinChemo-substanceCisplatinFluorouracilMitomycinChemo-substanceCisplatinFluorouracilMitomycinChemo-substanceCisplatinFluorouracilMitomycinNo. Substances12 RadiotherapySupportive therapySupportive substanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateSupportive substanceDexamethasoneFilgrastimFosaprepitantGranisetronNaCl 0.9%Sodium ThiosulfateNo. Substances235Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseintraoperativTherapy intentioncurativepalliativeRisksBleedingDyspneaElectrolyte DisturbanceEmetogenicity (MASCC/ESMO)FistulasHematotoxicityInfectionsPainThromboembolic Event only studiesPublicationAuthorElias DGhanipour LGötze TKuijpers Avan Driel WDiseaseLokalisiertes oder lokal fortgeschrittenes Magen-Ca oder Karzinom des gastroösopagealen Übergangs Typ II/IIINeudiagnostiziertes Ovarial-Ca, Eileiter-Ca oder Peritoneal-Ca, Stadium III mit neoadjuvanter Therapie, ECOG 0-2Peritonealkarzinom durch kolorektales Ca oder Pseudomyxoma peritonii, operabel, T1-T4, Stadium I-IVPeritonealkarzinose, sekundärPeritonealkarzinose ausgehend vom kolorektalen Karzinom, ECOG 0-2OriginDepartment of Gynecology, Netherlands Cancer Institute, AmsterdamDepartment of Surgical Oncology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, AmsterdamInstitut Gustave Roussy, Ville- juif, Service of Biostatistics, and Lyon- Sud Hospital, Lyon-SudPREVENT - FLOT9 trial of the AIO / CAOGI / ACOUppsala University, Uppsala, SwedenProtocols in Revision 5 protocols foundProtocols under revision.EPIC - Fluorouracil 400, Peritoneal Carcinomatosis, Secondary (PID2709 V1.0)HIPEC - Cisplatin 100, Ovarian ca (PID108 V2.1)HIPEC - Cisplatin 75, Adenocarcinoma Esophagogastric Junction and Stomach (PID2710 V1.1)HIPEC - Mitomycin 15 / Cisplatin 75, Peritoneal Carcinomatosis, Secondary (PID121 V3.0)HIPEC - Mitomycin 35, Peritoneal Carcinomatosis, Secondary (PID123 V2.0)
